The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives
In his new role, Shisher will lead Glenmark’s marketing initiatives, focusing on strengthening brand positioning, driving market expansion, and accelerating growth
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Subscribe To Our Newsletter & Stay Updated
